Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Kalaris TherapeuticsKLRS +0.76%12 Current Ratio is 12.19 as of Mar. 2026, which is 2% above its 10-year median of 11.98. GuruFocus rates KLRS with a GF Score™ of 12/100. Among 1,405 Biotechnology companies, Kalaris Therapeutics ranks better than 82.56% on this metric.
The current ratio is a liquidity ratio that measures a company's ability to pay short-term obligations. It is calculated as a company's Total Current Assets divides by its Total Current Liabilities. Kalaris Therapeutics's current ratio for the quarter that ended in Mar. 2026 was 12.19.
Kalaris Therapeutics has a current ratio of 12.19. It indicates the company may not be efficiently using its current assets or its short-term financing facilities. This may also indicate problems in working capital management.
The historical rank and industry rank for Kalaris Therapeutics's Current Ratio or its related term are showing as below:
KLRS'
s Current Ratio Range Over the Past 10 Years
Min: 0.11 Med: 11.98 Max: 14.31
Current: 12.19
During the past 4 years, Kalaris Therapeutics's highest Current Ratio was 14.31. The lowest was 0.11. And the median was 11.98.
KLRS's Current Ratio is ranked better than 82.56% of 1405
companies
in the Biotechnology industry
Industry Median: 3.83
vs KLRS: 12.19
Kalaris Therapeutics (NAS:KLRS) Current Ratio Explanation
The current ratio can give a sense of the efficiency of a company's operating cycle or its ability to turn its product into cash. Companies that have trouble getting paid on their receivables or have long inventory turnover can run into liquidity problems because they are unable to alleviate their obligations. Because business operations differ in each industry, it is always more useful to compare companies within the same industry.
Acceptable current ratios vary from industry to industry and are generally between 1 and 3 for healthy businesses.
The higher the current ratio, the more capable the company is of paying its obligations. A ratio under 1 suggests that the company would be unable to pay off its obligations if they came due at that point. While this shows the company is not in good financial health, it does not necessarily mean that it will go bankrupt - as there are many ways to access financing - but it is definitely not a good sign.
If all other things were equal, a creditor, who is expecting to be paid in the next 12 months, would consider a high current ratio to be better than a low current ratio, because a high current ratio means that the company is more likely to meet its liabilities which fall due in the next 12 months.
Kalaris Therapeutics Current Ratio Related Terms
Kalaris Therapeutics Current Ratio Historical Data
* Premium members only.
The historical data trend for Kalaris Therapeutics's Current Ratio can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
KLRS vs HRTX, VRCA, RLYB: Current Ratio Comparison
For the Biotechnology subindustry, Kalaris Therapeutics's Current Ratio, along with its competitors' market caps and Current Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Kalaris Therapeutics Current Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Kalaris Therapeutics's Current Ratio distribution charts can be found below:
* The bar in red indicates where Kalaris Therapeutics's Current Ratio falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Kalaris Therapeutics (KLRS) has a Current Ratio of 12.19 as of Mar. 2026. This is near median its historical median of 11.98. Over the past decade, Kalaris Therapeutics' Current Ratio has ranged from 0.11 to 14.31. According to the industry distribution chart, Kalaris Therapeutics ranks #245 out of 1405 companies in the Biotechnology industry, placing it in the top 17.4%.
Is Kalaris Therapeutics' Current Ratio too high?
Kalaris Therapeutics' current Current Ratio of 12.19 is near median its 10-year median of 11.98. Over the past 10 years, this metric has ranged from a low of 0.11 to a high of 14.31. The Biotechnology industry median Current Ratio is 3.83. Kalaris Therapeutics' value of 12.19 is 218.3% above this industry median. Based on the distribution chart, Kalaris Therapeutics ranks #245 out of 1405 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Kalaris Therapeutics has a GF Score™ of 12/100, reflecting its overall financial health beyond just this single metric.
How does Kalaris Therapeutics' Current Ratio compare to HRTX and VRCA?
According to the Biotechnology industry distribution chart, Kalaris Therapeutics ranks #245 out of 1405 companies for Current Ratio. This places Kalaris Therapeutics in the top 17% of its industry — outperforming the majority of peers. The industry median Current Ratio is 3.83. Kalaris Therapeutics' value of 12.19 is 218.3% above this benchmark. Historically, Kalaris Therapeutics' own Current Ratio has ranged from 0.11 to 14.31 over the past decade. While the company's 10-year median is 11.98 vs. the industry median of 3.83, Kalaris Therapeutics has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Current Ratio for a Biotechnology company?
The median Current Ratio among Biotechnology companies is 3.83, based on 1,405 companies in the industry. Companies in the top quartile (top 25%) have a Current Ratio significantly above this median, while those in the bottom quartile fall well below. However, Current Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Kalaris Therapeutics's current Current Ratio of 12.19 is 218.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Current Ratio mean?
A high Current Ratio can signal that a stock is expensive relative to its fundamentals. For the Biotechnology industry, the median Current Ratio is 3.83 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Kalaris Therapeutics's current Current Ratio is 12.19, which is near median its own 10-year median of 11.98. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Kalaris Therapeutics stock overvalued right now?
Kalaris Therapeutics (KLRS) has a current Current Ratio of 12.19. The current Current Ratio is 12.19, which is near median its 10-year median of 11.98 and 218.3% above the Biotechnology industry median of 3.83. Kalaris Therapeutics' overall GF Score™ is 12/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Current Ratio calculated?
Current Ratio is calculated from a company's financial statements. For Kalaris Therapeutics (KLRS), the current Current Ratio is 12.19 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Kalaris Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing and commercializing therapeutics for prevalent retinal diseases. The company is developing TH103, a novel, clinical-stage anti-vascular endothelial growth factor VEGF drug, engineered to potentially provide longer-lasting and increased anti-VEGF activity in patients with exudative and neovascular retinal diseases. TH103 is a fully humanized recombinant fusion protein, functioning as a decoy receptor (a VEGF trap), leveraging salient molecular properties of the human body's native, highest affinity VEGF receptor 1.
12GF Score
Get the complete analysis for KLRS
Current Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
KLRS has been successfully added to your 
